The Value of Fibroblast Growth Factor 10 and Novel Fgf10as As A Prognostic Biomarker in Colorectal Cancer Patients

Background and aim: colorectal cancer (crc) imposes great health burdens around the world. growth factors contribute to cell growth, differentiation, angiogenesis, and most importantly tumor formation in many types of cancers. natural antisense transcripts (nats) are inclusively expressed in the genome and are predicted to play a major role in cancer progression. the present study aimed at evaluating the relationship of fibroblast growth factor 10 (fgf10) and fgf10as expression with clinicopathological features in crc progression.methods: this study was navigated on 150 crc tumor tissues and 150 adjacent non-tumor tissues according to the inclusion and exclusion criteria. the expression levels of fgf10 and fgf10as were evaluated by the strand-specific real-time quantitative polymerase chain reaction (rt-qpcr). immunohistochemistry analysis was performed systematically for evaluating fgf10 expression. the collected data were analyzed using prism 8.02 and spss 23.results: a significant increase and decrease in expression levels were observed in fgf10 (p< 0.0001) and fgf10as (p> 0.01) in tumoral tissues, in comparison with the adjacent normal tissues. besides, overexpression of fgf10 and diminution in fgf10as expression were strongly correlated with the tnm stage (p< 0.0051 and p< 0.02, respectively) and vascular invasion (p< 0.03 and p< 0.01, respectively). moreover, the area under the roc curve for the prognostic value of fgf10 was about 0.89 (95% confidence interval, 0.877–0.941). the results of linear regression analysis confirmed a negative correlation between fgf10 expression and its antisense transcript (r= -0.02).conclusion: the correlation between the expression levels of fgf10 and fgf10as in tumor tissues and the adjacent normal tissues suggested that sense and antisense fgf rnas could be significant prognostic biomarkers for elevating survival rates and treatment improvement.